TG Therapeutics, Inc. (TGTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
TGTX POWR Grades
- TGTX scores best on the Growth dimension, with a Growth rank ahead of 62.76% of US stocks.
- The strongest trend for TGTX is in Stability, which has been heading down over the past 179 days.
- TGTX's current lowest rank is in the Stability metric (where it is better than 2.79% of US stocks).
TGTX Stock Summary
- With a price/sales ratio of 225.47, Tg Therapeutics Inc has a higher such ratio than 98.7% of stocks in our set.
- As for revenue growth, note that TGTX's revenue has grown 4,300.66% over the past 12 months; that beats the revenue growth of 99.6% of US companies in our set.
- In terms of volatility of its share price, TGTX is more volatile than 94.76% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to Tg Therapeutics Inc are INMB, BBIO, VIR, FIXX, and ARGX.
- TGTX's SEC filings can be seen here. And to visit Tg Therapeutics Inc's official web site, go to www.tgtherapeutics.com.
TGTX Valuation Summary
- In comparison to the median Healthcare stock, TGTX's price/sales ratio is 42050% higher, now standing at 1601.7.
- TGTX's price/earnings ratio has moved down 7.9 over the prior 138 months.
- TGTX's EV/EBIT ratio has moved down 5.4 over the prior 138 months.
Below are key valuation metrics over time for TGTX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| TGTX | 2021-08-31 | 1601.7 | 10.1 | -11.2 | -10.3 |
| TGTX | 2021-08-30 | 1580.4 | 10.0 | -11.1 | -10.2 |
| TGTX | 2021-08-27 | 1601.7 | 10.1 | -11.2 | -10.3 |
| TGTX | 2021-08-26 | 1491.1 | 9.4 | -10.4 | -9.6 |
| TGTX | 2021-08-25 | 1534.2 | 9.7 | -10.8 | -9.9 |
| TGTX | 2021-08-24 | 1520.6 | 9.6 | -10.7 | -9.8 |
TGTX Growth Metrics
- Its 2 year net cashflow from operations growth rate is now at -62.38%.
- Its 5 year price growth rate is now at 157.91%.
- Its 3 year net income to common stockholders growth rate is now at -168.58%.
The table below shows TGTX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-12-31 | 6.689 | -295.634 | -348.101 |
| 2021-09-30 | 4.406 | -260.751 | -342.98 |
| 2021-06-30 | 2.414 | -250.082 | -344.506 |
| 2021-03-31 | 0.907 | -233.747 | -318.893 |
| 2020-12-31 | 0.152 | -214.507 | -279.381 |
| 2020-09-30 | 0.152 | -192.874 | -230.735 |
TGTX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- TGTX has a Quality Grade of D, ranking ahead of 7.5% of graded US stocks.
- TGTX's asset turnover comes in at 0.005 -- ranking 411th of 681 Pharmaceutical Products stocks.
- TMBR, ATRA, and EVOK are the stocks whose asset turnover ratios are most correlated with TGTX.
The table below shows TGTX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.005 | 0.881 | -27.668 |
| 2021-03-31 | 0.002 | 0.847 | -42.516 |
| 2020-12-31 | 0.000 | 1.000 | -36.140 |
| 2020-09-30 | 0.001 | 1.000 | -86.159 |
| 2020-06-30 | 0.001 | 1.000 | -22.399 |
| 2020-03-31 | 0.001 | 1.000 | -12.310 |
TGTX Price Target
For more insight on analysts targets of TGTX, see our TGTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $75.33 | Average Broker Recommendation | 1.44 (Moderate Buy) |
TGTX Stock Price Chart Interactive Chart >
TGTX Price/Volume Stats
| Current price | $5.17 | 52-week high | $41.00 |
| Prev. close | $5.05 | 52-week low | $4.73 |
| Day low | $4.74 | Volume | 3,397,200 |
| Day high | $5.26 | Avg. volume | 2,642,769 |
| 50-day MA | $7.87 | Dividend yield | N/A |
| 200-day MA | $18.23 | Market Cap | 746.73M |
TG Therapeutics, Inc. (TGTX) Company Bio
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company was founded in 1993 and is based in New York, New York.
Latest TGTX News From Around the Web
Below are the latest news stories about Tg Therapeutics Inc that investors may wish to consider to help them evaluate TGTX as an investment opportunity.
AdaptHealth Corp. (AHCO) Q4 Earnings Miss EstimatesAdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of -62.50% and 1.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2021 Financial Results and Business UpdateConference call to be held Tuesday, March 1, 2022 at 8:30 AM ETNEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Tuesday, March 1, 2022 at 8:30 AM ET to discuss results for the fourth quarter and year-end 2021 and provide a business outlook for 2022. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-2 |
2 Wildly Oversold Stocks That Could Explode HigherThe stock market is often an exercise in reverse psychology. When a stock goes up, investors instinctively want to get a piece of the action. Likewise, when a stock drifts to the bottom, the natural inclination is to run away. But any investor worth their salt knows they need to battle against those natural impulses as the bottom is often the most appealing starting point; because it is from there that the real gains are made. |
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual ForumNEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held February 24 – 26, 2022, in West Palm Beach, Florida. Abstracts are now available online and can be access |
Ublituximab In MS Is The Heart Of TG Therapeutics, And The Heart Is SafeTG Therapeutics (TGTX) is giving the biopharma market the scare of its life, with the FDA looking more and more likely to come up with a negative opinion on the approval of Ublituximab+Umbralisib (Ukoniq), also known as U2, in Chronic Lymphocytic Lymphoma or CLL. The FDA’s beef is directed against... |
TGTX Price Returns
| 1-mo | -22.95% |
| 3-mo | -47.78% |
| 6-mo | -77.87% |
| 1-year | -85.17% |
| 3-year | -25.07% |
| 5-year | -57.10% |
| YTD | -72.79% |
| 2021 | -63.48% |
| 2020 | 368.65% |
| 2019 | 170.73% |
| 2018 | -50.00% |
| 2017 | 76.34% |
Continue Researching TGTX
Want to see what other sources are saying about Tg Therapeutics Inc's financials and stock price? Try the links below:Tg Therapeutics Inc (TGTX) Stock Price | Nasdaq
Tg Therapeutics Inc (TGTX) Stock Quote, History and News - Yahoo Finance
Tg Therapeutics Inc (TGTX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...